ADMA Biologics, Inc. (ADMA)
9.545
-0.30
(-3.00%)
USD |
NASDAQ |
Aug 24, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Gross Profit Margin (Quarterly) : 69.31% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 69.31% |
| March 31, 2026 | 70.48% |
| December 31, 2025 | 63.78% |
| September 30, 2025 | 56.31% |
| June 30, 2025 | 55.09% |
| March 31, 2025 | 53.20% |
| December 31, 2024 | 53.86% |
| September 30, 2024 | 49.76% |
| June 30, 2024 | 53.47% |
| March 31, 2024 | 47.53% |
| December 31, 2023 | 41.81% |
| September 30, 2023 | 36.38% |
| June 30, 2023 | 27.46% |
| March 31, 2023 | 28.70% |
| December 31, 2022 | 28.01% |
| September 30, 2022 | 23.07% |
| June 30, 2022 | 22.39% |
| March 31, 2022 | 11.97% |
| December 31, 2021 | 12.63% |
| September 30, 2021 | 1.00% |
| June 30, 2021 | -6.62% |
| March 31, 2021 | -11.84% |
| December 31, 2020 | -49.49% |
| September 30, 2020 | -17.11% |
| June 30, 2020 | -75.59% |
| Date | Value |
|---|---|
| March 31, 2020 | -66.75% |
| December 31, 2019 | -2.74% |
| September 30, 2019 | -12.53% |
| June 30, 2019 | -63.12% |
| March 31, 2019 | -172.5% |
| December 31, 2018 | -179.9% |
| September 30, 2018 | -121.6% |
| June 30, 2018 | -149.0% |
| March 31, 2018 | -253.5% |
| December 31, 2017 | -22.07% |
| September 30, 2017 | -178.0% |
| June 30, 2017 | -76.71% |
| March 31, 2017 | -17.76% |
| December 31, 2016 | -2.32% |
| September 30, 2016 | -9.55% |
| June 30, 2016 | 40.83% |
| March 31, 2016 | -19.92% |
| December 31, 2015 | 40.18% |
| September 30, 2015 | 39.93% |
| June 30, 2015 | -43.77% |
| March 31, 2015 | -30.24% |
| December 31, 2014 | -45.49% |
| September 30, 2014 | -38.08% |
| June 30, 2014 | -17.42% |
| March 31, 2014 | -14.03% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Erasca, Inc. | -- |
| Krystal Biotech, Inc. | 93.46% |
| Vericel Corp. | 72.82% |
| Emergent BioSolutions, Inc. | 51.22% |
| Exelixis, Inc. | 96.71% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 40.13% |
| Return on Assets | 27.17% |
| Return on Invested Capital | 30.60% |
| Profit Margin (Quarterly) | 30.40% |
| Operating Margin (Quarterly) | 42.16% |
| Return on Net Operating Assets | 39.86% |